Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Men's Hormone Health

CoverageMen's Hormone Health

Does testosterone therapy worsen obstructive sleep apnea?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Trial data specifically powering sleep apnea endpoints are limited.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

TRT and OSA▼

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.

Testosterone sleep apnea risk▼

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.

Does testosterone in men affect sleep apnea?▼

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.

testosterone men obstructive sleep apnea OSA▼

Testosterone may worsen sleep apnea in predisposed men. Screening and monitoring for OSA is recommended before and during therapy, especially when symptoms emerge or hematocrit rises.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 13 relevant studies.

Overall finding

6 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association. 3 studies address bone mineral density, with weighted findings showing no meaningful effect. 2 studies address venous thromboembolism, with weighted findings showing no meaningful effect. 1 study addresses weight / body composition, with weighted findings showing unclear findings. 6 randomized or systematic-review reports and 7 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Positive link

Sleep-related cognitive symptoms

high · 6 studies

6 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association.

Mixed measurement

Studies

PMID 35904664PMID 34536053PMID 34999717PMID 31988219PMID 31495240PMID 25873947
Reassuring

Bone mineral density

high · 3 studies

3 studies address bone mineral density, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 19820017PMID 26901812PMID 11730247
Reassuring

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37326322PMID 26205547
Unclear

Weight / body composition

moderate · 1 study

1 study addresses weight / body composition, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 35904664
Unclear

Quality of life

moderate · 1 study

1 study addresses quality of life, with weighted findings showing unclear findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 35904664
Reassuring

Fractures

moderate · 1 study

1 study addresses fractures, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 19820017

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 10. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Most studies agree on quality of life (unclear findings), while bone mineral density findings are no meaningful effect and more consistent across domains.

Supports main conclusion: 1 · Neutral / mixed: 12 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • The results indicated that OSA is significantly correlated with the decrease in serum testosterone levels in men.
  • Testosterone therapy should be individualized with cardiovascular risk assessment and monitoring rather than categorically avoided.
  • Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
  • It has generally been held that estrogen and testosterone are the major sex steroids regulating bone metabolism in women and men, respectively.

Risks & harms

4 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Trial data specifically powering sleep apnea endpoints are limited.
  • Trial data specifically powering sleep apnea endpoints are limited.

Clinical takeaway

Screen for obstructive sleep apnea before and during testosterone therapy, especially when snoring, daytime somnolence, or rising hematocrit appear. Treating underlying OSA may improve safety and tolerability without abandoning indicated testosterone replacement.

Positive link

Sleep-related cognitive symptoms?

A positive association

high[35904664 · 34536053 · 34999717 · 31988219 · 31495240 · 25873947]

Reassuring

Bone mineral density?

No meaningful effect

high[19820017 · 26901812 · 11730247]

Reassuring

Venous thromboembolism?

No meaningful effect

moderate[37326322 · 26205547]

Unclear

Weight / body composition?

Unclear findings

moderate[35904664]

Unclear

Quality of life?

Unclear findings

moderate[35904664]

Reassuring

Fractures?

No meaningful effect

moderate[19820017]

Unclear

Hematocrit / erythrocytosis?

Unclear findings

limited[35467476]

Unclear

Fertility / spermatogenesis?

Unclear findings

limited[27855957]

6 randomized or systematic-review reports and 7 observational studies address treatment. Weighted treatment findings show mixed findings.

6 RCT / systematic review · 7 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

14 analyzed studies

Strongest evidence

Supporting literature

Cardiovascular Safety of Testosterone-Replacement Therapy.

Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

Testosterone replacement therapy and cardiovascular disease.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Hormone Health.

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

11 linked studies

Does testosterone therapy increase prostate cancer risk?

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

14 linked studies

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

14 linked studies

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

14 linked studies

Go deeper on Men's Hormone Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Men's Hormone HealthView pricing